EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Indications of the SERPINE 1 variant rs1799768’s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration

Muhammer Özgür Çevik iD, Zühal Mert Altuntaş, Sadık Görkem Çevik

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0317511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Muhammer Özgür Çevik und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine, Adiyaman University, Adiyaman, Türkiye. Hauptthemen laut MEDLINE: Plasminogen Activator Inhibitor 1, Vascular Endothelial Growth Factor A, Macular Degeneration, Angiogenesis Inhibitors. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age-related macular degeneration (AMD) is a retinal disease prevalent in the elderly population, with two main subtypes: dry (non-exudative) and neovascular (wet or exudative). Neovascular AMD (nAMD) has a more debilitating prognosis than dry AMD, making it the third leading cause of blindness. Intravitreal injections of anti-vascular endothelial growth factor (IV anti-VEGF) are the most effective and widely accepted treatment for nAMD. However, a significant number of nAMD patients exhibit suboptimal responses to IV anti-VEGF therapy, with the underlying mechanisms not yet fully understood. We hypothesized that genetic polymorphisms associated with blood hypercoagulation may also contribute to suboptimal responses to IV anti-VEGF therapy. This study recruited 20 nAMD patients, who were divided into two groups based on their treatment responses after four years: 10 patients with suboptimal responses to IV anti-VEGF therapy and 10 patients with optimal responses. After obtaining institutional ethics board approval, we retrospectively evaluated relevant clinical records of twenty patients diagnosed with nAMD. Patient clinical data were accessed between 20th March 2021 -1st April 2021 for research purposes only. We genotyped peripheral blood DNA from each patient for hypercoagulation-related polymorphisms, including Factor V Leiden (rs6025), prothrombin c.20210G>A (rs1799963), MTHFR A1298C (rs1801131), MTHFR C677T (rs1801133), and SERPINE 1 (PAI-1-675 4G/5G) (rs1799768), and statistically compared the frequencies. Heterozygous and homozygous mutations in the SERPINE1 gene specifically PAI-1 promoter region PAI-1-675 4G/5G (rs1799768) were identified as risk factors for resistance to IV anti-VEGF therapy in nAMD patients (χ² test, p = 0.006). No other polymorphisms of the above-mentioned genes were statistically significant (p > 0.05). The failure of IV anti-VEGF therapy in nAMD patients may be influenced by various factors, one of which may be the inherited PAI-1-675 4G/5G (rs1799768) polymorphisms which normally known to contribute hypercoagulation. Further research involving a larger cohort is necessary to uncover the interplay between hereditary factors and other elements contributing to the inefficacy of IV anti-VEGF therapy in nAMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasminogen Activator Inhibitor 1Vascular Endothelial Growth Factor AMacular DegenerationAngiogenesis InhibitorsDrug ResistanceHumansFemaleMaleAgedPolymorphism, Single NucleotideAged, 80 and overRetrospective Studies

Substanzen

Plasminogen Activator Inhibitor 1Vascular Endothelial Growth Factor ASERPINE1 protein, humanAngiogenesis InhibitorsVEGFA protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine, Adiyaman University, Adiyaman, Türkiye.
  • Department of Medical Genetics, Faculty of Medicine, Mersin University, Mersin, Türkiye.
  • Department of Ophthalmology, Beyoglu Eye Research Hospital Intravitreal Surgery Unit, University of Health Sciences, Istanbul, Türkiye.

ORCID-Profile: Muhammer Özgür Çevik

Zitieren

APA

Çevik, M. Ö., Mert Altuntaş, Z., & Çevik, S. G. (2025). Indications of the SERPINE 1 variant rs1799768’s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration. PLOS ONE. https://doi.org/10.1371/journal.pone.0317511

Vancouver

Çevik MÖ, Mert Altuntaş Z, Çevik SG. Indications of the SERPINE 1 variant rs1799768’s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration. PLOS ONE. 2025. doi:10.1371/journal.pone.0317511

BibTeX
@article{evik2025,
  author = {Çevik, Muhammer Özgür and Mert Altuntaş, Zühal and Çevik, Sadık Görkem},
  title = {Indications of the SERPINE 1 variant rs1799768’s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0317511}
}
Kostenlos starten →